[Disclosure] Celltrion (068270) Obtains South Korean Phase 3 Clinical Trial Approval for ‘CT-P13 SC’ (Remsima SC) in Pediatric Crohn’s Disease

Source: Financial Supervisory Service Dart System / 2025-02-24

Disclosure Type: Key Management Matters Related to Investment Decisions

💡 3-Second Summary

Celltrion has obtained approval for its Phase 3 clinical trial application (IND) from the Ministry of Food and Drug Safety (MFDS) of South Korea for ‘CT-P13 SC’, a subcutaneous formulation of infliximab, in pediatric patients with active Crohn’s disease.

📊 1. [Key Disclosure Content & Major Figures Summary]

• Trial Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy in Pediatric Patients with Moderately to Severely Active Crohn’s Disease
• Clinical Phase & Agency: Phase 3 Clinical Trial / Ministry of Food and Drug Safety (MFDS) of South Korea
• Target Indication: Pediatric Patients (aged 6-17) with Moderately to Severely Active Crohn’s Disease
• Timeline:
  • Application Date: September 30, 2024
  • Approval Date: February 21, 2025 (Official document confirmed date)
• Trial Design & Scale:
  • Number of Subjects: 243 patients
  • Trial Duration: Treatment period of 106 weeks
  • Study Design: Randomized, double-blind
• Trial Objective & Background:
  • Objective: To compare and evaluate the efficacy of low-dose and high-dose maintenance therapy of CT-P13 SC administered every two weeks to achieve clinical remission and endoscopic response at Week 54.
  • Background: While CT-P13 SC has completed Phase 3 trials for adult patients (ulcerative colitis and Crohn’s disease) and secured marketing authorization in multiple markets including the US and Europe, this study aims to expand therapeutic options to the pediatric population.

📈 2. [Expert Perspective: What This Means for Investors]

• Initiation of Clinical Evaluation for Pediatric Indication: This disclosure confirms that CT-P13 SC, which is already authorized for adult indications in the US and Europe, has cleared the regulatory process for its pediatric Crohn’s disease Phase 3 trial in South Korea. This allows the company to begin gathering domestic clinical data for this specific younger demographic.
• Long-Term Trial Structure and Observation: The approved study design involves a 106-week treatment program with 243 subjects to evaluate low-dose and high-dose administration. Consequently, commercial or operational milestones from this study will require a long-term clinical and observation timeline, primarily focusing on the interim Week 54 endpoints.
• Statistical R&D and Clinical Risks: As specified in the disclosure’s caution notes, the historical probability of a clinical candidate obtaining final marketing authorization is approximately 10%. Investors must note that unfavorable clinical results can lead to adjustments or cancellation of commercialization plans, keeping the inherent risks of clinical development in perspective.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has secured regulatory approval from the South Korean MFDS for its Phase 3 clinical trial evaluating its subcutaneous infliximab formulation, ‘CT-P13 SC’, in pediatric Crohn’s disease. This authorization, received five months after filing the application in September 2024, establishes the official framework to expand the therapeutic scope of this biological candidate from adult cohorts to pediatric patients.

The primary check point for investors moving forward is the actual initiation of the Phase 3 trial, such as the enrollment and dosing of the first patient under the approved protocol. Since the study involves a long-term tracking structure with a 106-week treatment duration, closely monitoring whether clinical progression meets the regulatory schedule will be essential.

Additionally, because the general statistical success rate for a candidate to successfully secure final marketing approval stands at approximately 10%, investors should avoid interpreting this clinical plan approval as an immediate indicator of commercial success. Following the objective clinical metrics and updates published in upcoming periodic corporate reports remains the recommended approach.

📢 Disclaimer & Sources

Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.

Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.

Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.